The systemic face of airway diseases: The role of C-reactive protein

European Respiratory Journal

Volumn 27, Issue 5, 2006, Pages 877-879

  Wouters, E F M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; STEROID;

ARTERIAL OXYGEN TENSION; ASTHMA; BEHAVIOR MODIFICATION; CACHEXIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EDITORIAL; ENERGY EXPENDITURE; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; HUMAN; LYMPHOCYTOSIS; MUSCLE ATROPHY; MUSCLE DISEASE; MUSCLE STRENGTH; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RESPIRATORY AIRFLOW; RESPIRATORY TRACT INFLAMMATION; RISK FACTOR; SYSTEMIC DISEASE;

ASTHMA; C-REACTIVE PROTEIN; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33845507066     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00032706     Document Type: Editorial

References (23)

1. Wouters EF. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax 2002; 57: 1067-1070.
2. de Torres JP, Cordoba-Lanus E, López-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006; 27: 902-907.
3. Takemura M, Matsumoto H, Niimi A, et al. High sensitivity C-reactive protein in asthma. Eur Respir J 2006; 27: 908-912.
4. Yende S, Waterer GW, Tolley EA, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006; 61: 10-16.
5. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17-22.
6. Pinto-Plata VM, Mullerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61: 23-28.
7. Pedersen BK, Steensberg A, Fischer C, et al. The metabolic role of IL-6 produced during exercise: is IL-6 an exercise factor? Proc Nutr Soc 2004; 63: 263-267.
8. Kony S, Zureik M, Driss F, Neukirch C, Leynaert B, Neukirch F. Association of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): a population based study. Thorax 2004; 59: 892-896.
9. Olafsdottir IS, Gislason T, Thjodleifsson B, et al. C reactive protein levels are increased in non-allergic but not allergic asthma: a multicentre epidemiological study. Thorax 2005; 60: 451-454.
10. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003; 114: 758-762.
11. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29: 439-493.
12. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
13. Dev D, Wallace E, Sankaran R, et al. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 1998; 92: 664-667.
14. Cano NJ, Pichard C, Roth H, et al. C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest 2004; 126: 540-546.
15. Anderson GP. COPD, asthma and C-reactive protein. Eur Respir J 2006; 27: 874-876.
16. Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 2005; 128: 3618-3624.
17. Pankow JS, Folsom AR, Cushman M, et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001; 154: 681-689.
18. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002; 162: 217-219.
19. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002; 3: 14-19.
20. MacGregor AJ, Gallimore JR, Spector TD, Pepys MB. Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem 2004; 50: 130-134.
21. Retterstol L, Eikvar L, Berg K. A twin study of C-reactive protein compared to other risk factors for coronary heart disease. Atherosclerosis 2003; 169: 279-282.
22. Sin DD, Man SF, McWilliams A, Lam S. Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer. Am J Respir Crit Care Med 2006; 173: 535-539.
23. Sin DD, Man SF. Can inhaled steroids mend a broken heart in chronic obstructive pulmonary disease? Eur Respir J 2005; 25: 589-590.